ArticleScientific reports2025
Enhanced hemocompatibility, antimicrobial and anti-inflammatory properties of biomolecules stabilized AgNPs with cytotoxic effects on cancer cells.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Biogenic Silver Nanoparticles Mediated by Phytoconstituents of the Edible Spice Pimpinella anisum: Characterization and In Vitro, In Vivo, and In Silico Biological Evaluation.Journal of food science · 2026Article
- Are Silver and Gold Nanoparticles Obtained by 'Green' Synthesis Biocompatible?Nanomaterials (Basel, Switzerland) · 2026Review
- Antibacterial and antibiofilm activities of curcumin-mediated green-synthesised silver nanoparticles against Methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.BMC biotechnology · 2026Article
- Radiolytic Synthesis of Chitosan-Stabilized Silver Nanoparticles via Electron Beam Irradiation for Enhanced Antibacterial Activity AgainstInternational journal of molecular sciences · 2026Article
- Network pharmacology and molecular docking reveal antiviral mechanisms of silver nanoparticles synthesized by Oscillatoria sp. against HCV pathogenesis.Scientific reports · 2025Article
- Antimicrobial Nanoparticles Against Superbugs: Mechanistic Insights, Biomedical Applications, and Translational Frontiers.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the current research, we developed a safe method using Iranian yarrow extract for the synthesis of silver nanoparticles (IY-AgNPs) as reducing and stabilizing agents in different conditions. The prepared and stabilized IY-AgNPs under optimal conditions were characterized using FT-IR, XRD, TEM, and UV-vis techniques. Also, the blood-clotting, hemolytic, antioxidant, bactericidal and, fungicidal properties, cytotoxicity effects and inhibition of protein denaturation efficiency of IY-AgNPs were assessed in vitro. The stabilized IY-AgNPs with spherical shape and an average particle size of 19. 25 ± 7.9 nm did not show any hemolytic potential below 1000 µg/mL. These hemo-compatible NPs showed good blood-clotting ability by reducing clotting time (6 min relative to the control). These particles excellently inhibited the denaturation of bovine serum albumin (BSA) by 69.3-80.7% at concentrations ranging from 31.25 to 500 µg/mL compared to a reference drug. The outcomes showed that the IC50 values of IY-AgNPs were below 12.5 µg/mL against A375 cells and between 25 and 50 µg/mL against MCF-7 cancer cells. In addition, IY-AgNPs were bactericidal against Escherichia coli, Pseudomonas aeruginosa and Staphylococcus aureus (especially), and were fungicidal against Candida albicans. Biosynthesized IY-AgNPs indicated a significant antioxidant activity (63.2%) at a concentration of 350 µg/mL. These attained results suggested that bio/hemo-compatible IY-AgNPs may be a promising candidate for applications in the medicinal fields (particularly for wound healing) as anti-bleeding, antimicrobial, antioxidant, anti-inflammatory, and anticancer agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.